图片名称

Individualized target detection scheme for non-small cell lung cancer


Currently, the morbidity and mortality of lung cancer ranks first among all malignant tumors in China. Non-small cell lung cancer patients account for 80-85% of the total number of lung cancer patients, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, its cancer cells grow and divide slowly and spread and metastasize relatively late.

 

type of drug target gene sample type
targeted drugs Gefitinib
Erlotinib

EGFR

Fresh tissue, paraffin-embedded tissue, plasma

K-ras

Fresh tissue, paraffin-embedded tissue, plasma

B-raf

PIK3CA

cetuximab
panitumumab

K-ras

N-ras

Crizotinib

ALK

Fresh tissue, paraffin-embedded tissue, plasma

ROS1

RET融合

Chemotherapy drugs Platinum

ERCC1

Fresh tissue, paraffin-embedded tissue

BRCA1

TP53

Paclitaxel
Vinblastine etc.

STMN1

TUBB3

Fluorine

TYMS

TYMP

DPYD

Etoposide

TOP2A

Gemcitabine

RRM1

irinotecan

UGT1A1

Whole blood